Tyler J. Nielsen
YOU?
Author Swipe
View article: 182 DetermaIO stratifies the tumor microenvironment and immunotherapy response in melanoma: a pilot study including cutaneous and uveal subtypes
182 DetermaIO stratifies the tumor microenvironment and immunotherapy response in melanoma: a pilot study including cutaneous and uveal subtypes Open
View article: Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Purpose:We assessed the 27-gene RT-qPCR–based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neo…
View article: Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Data S1. FPKM RNA-Seq data for the genes included in the IO score signature.
View article: Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 4. Univariate regression of pCR according to TNBC subtypes in the RNA-Seq cohort. One-vs-all approach was applied.
View article: Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 7. Association of TNBC subtypes and IO classifications. A) Frequency of RT-qPCR DetermaIO class by TNBC subtype; B) Frequency of RNAseq IO classes by TNBC subtype. C) Multivariable logistic regression model with TNBC s…
View article: Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 6. Comparison of TNBC subtype classification systems. A) Sankey plot showing the overlap between the TNBC subtype classification according to Ring and colleagues and the original TNBCtypes from Lehmann and colleagues B…
View article: Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 4. Baseline RNA-Seq IO score. A) Frequency of IO+ and IO− patients in the overall NeoTRIP population (left) and by treatment arm (right); B) Association between IO classes and PD-L1 status (left) or sTILs (right); C) p…
View article: Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 1. Quality control of NeoTRIP RNA-Seq data. Boxplots showing the distribution of read depth of targeted coding regions by arm and response status. Dots represent the read depth of single samples. The horizontal grey da…
View article: Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 2. Comparison of RT-qPCR DetermaIO and RNA-Seq IO scores. A) Scatter plot showing the relation between continuous IO scores. Concordance and correlation coefficient = 0.94; 95% CI = 0.92 − 0.95; B) Contingency plot of …
View article: Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 3. Univariate and multivariable regression of pCR according to NGS-based IO score in the RNA-Seq cohort.
View article: Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 3. Continuous baseline RT-qPCR DetermaIO score. Distribution of continuous IO score by treatment arm and pCR status. P-values by logistic regression.
View article: Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 5. Comparison of IO score with additional immune signatures. A) Correlation of RT-qPCR and RNA-Seq continuous IO score in the respective NeoTRIP cohorts with previously published immune signatures; B) Comparison of uni…
View article: Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 1. List of 27 genes of the DetermaIO assay.
View article: Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 5. Multivariable regression of pCR according to NGS-based IO score and TNBC subtypes in the RNA-Seq cohort. For TNBC subtypes LAR was taken as reference group.
View article: Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 2. Patients’ characteristics of the NeoTRIP trial in the RNA-Seq and RT-qPCR cohorts.
View article: The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Purpose: We assessed the 27-gene RT-qPCR–based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared ne…
View article: Supplementary Table S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Table S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
View article: Data from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Data from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Background: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5fluoruracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of metastatic colorectal cance…
View article: Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Consort diagram of the study. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
View article: Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLF…
View article: Supplementary Table S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Table S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
View article: Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Consort diagram of the study. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.
View article: Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLF…
View article: Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates F…
View article: Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer Open
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b). Legend: HR: hazard ratio, NR: not reached. Control arm indicates F…
View article: A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer Open
Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bio…
View article: Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer Open
Kaplan Meier estimates of progression-free survival in the pMMR population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FOLFO…
View article: Data from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Data from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer Open
Purpose:AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colo…
View article: Supplementary Table S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Supplementary Table S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer Open
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.
View article: Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer Open
Kaplan Meier estimates of progression-free survival in the overall population (optimized cut-point), according to IO status (a) and to both IO status and treatment arm (b).Legend: HR: hazard ratio, NR: not reached. Control arm indicates FO…